Anika Therapeutics (ANIK) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.11 --0%
EPS Growth %: -125.0%
Financial Fact:
Basic weighted average common shares outstanding: 14.63M
Today's EPS Names:
RCBC, GASS, YSG, More
EPS Growth %: -125.0%
Financial Fact:
Basic weighted average common shares outstanding: 14.63M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.46, $0.01 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $27.2 million versus the consensus estimate of $28.92 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Stifel Reiterates Buy Rating on Palo Alto Networks (PANW)
- Kepler Cheuvreux Downgrades Thyssenkrupp Nucera AG (NCH2:GR) to Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
